Cycloset (Bromocriptine Mesylate) Patent Expiration, LOE Window & CMS Spending

Cycloset (Bromocriptine Mesylate) by Veroscience: FDA Orange Book LOE 2032-04-30, 2 AB generics, $2.8M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVeroscience
FDA Application & PathwayN020866 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-04-30
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$2.8M
2024 Medicare Part D Spend$2.4M
2024 Medicaid Spend$369K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 24.9% 2-yr change)